|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q47146942
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241120235933.0 |
|
008
|
|
|
241120nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q47146942
|
|
024
|
|
|
‡a
0000-0003-1492-4506
‡2
orcid
|
|
024
|
|
|
‡a
35074491500
‡2
scopus
|
|
024
|
|
|
‡a
56587477000
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q47146942
|
|
100
|
0 |
|
‡a
Cláudia S. Marques
‡c
researcher
‡9
en
|
|
375
|
|
|
‡a
2
‡2
iso5218
|
|
400
|
0 |
|
‡a
Cláudia S. Marques
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's A sporozoite-based vaccination platform against human malaria
|
|
670
|
|
|
‡a
Author's Analysis of the protective potential of antigens released by Leishmania
|
|
670
|
|
|
‡a
Author's Analysis of the protective potential of antigens released by Leishmania (Viannia) shawi promastigotes.
|
|
670
|
|
|
‡a
Author's Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.
|
|
670
|
|
|
‡a
Author's CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors
|
|
670
|
|
|
‡a
Author's Detection of Toxoplasma gondii oocysts in fresh vegetables and berry fruits
|
|
670
|
|
|
‡a
Author's Differential expression of cytokine genes among sickle-cell-trait
|
|
670
|
|
|
‡a
Author's Differential expression of cytokine genes among sickle-cell-trait (HbAS) and normal (HbAA) children infected with Plasmodium falciparum.
|
|
670
|
|
|
‡a
Author's Efficacy of the liposome trifluralin in the treatment of experimental canine leishmaniosis.
|
|
670
|
|
|
‡a
Author's HER2-positive feline mammary carcinoma
|
|
670
|
|
|
‡a
Author's Histopathology, humoral and cellular immune response in the murine model of Leishmania (Viannia) shawi
|
|
670
|
|
|
‡a
Author's Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response.
|
|
670
|
|
|
‡a
Author's Immunization with the Leishmania infantum recombinant cyclophilin protein 1 confers partial protection to subsequent parasite infection and generates specific memory T cells.
|
|
670
|
|
|
‡a
Author's In vitro cytotoxicity evaluation of resveratrol-loaded nanoparticles: Focus on the challenges of in vitro methodologies
|
|
670
|
|
|
‡a
Author's Intra-specific variability of virulence in Leishmania infantum zymodeme MON-1 strains.
|
|
670
|
|
|
‡a
Author's New insights into neutrophil and Leishmania infantum in vitro immune interactions.
|
|
670
|
|
|
‡a
Author's Potential benefits of a sulfated resveratrol derivative for topical application.
|
|
670
|
|
|
‡a
Author's Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes
|
|
670
|
|
|
‡a
Author's Studies in a co-infection murine model of Plasmodium chabaudi chabaudi and Leishmania infantum: interferon-gamma and interleukin-4 mRNA expression.
|
|
670
|
|
|
‡a
Author's Sustained drug release by contact lenses for glaucoma treatment-a review.
|
|
670
|
|
|
‡a
Author's Tissue regulation of somitic colloid-like1 gene expression
|
|
909
|
|
|
‡a
(orcid) 0000000314924506
‡9
1
|
|
909
|
|
|
‡a
(scopus) 35074491500
‡9
1
|
|
909
|
|
|
‡a
(scopus) 56587477000
‡9
1
|
|
919
|
|
|
‡a
sporozoitebasedvaccinationplatformagainsthumanmalaria
‡A
A sporozoite-based vaccination platform against human malaria
‡9
1
|
|
919
|
|
|
‡a
histopathologyhumoralandcellularimmuneresponseinthemurinemodelofleishmaniavianniashawi
‡A
Histopathology, humoral and cellular immune response in the murine model of Leishmania (Viannia) shawi
‡9
1
|
|
919
|
|
|
‡a
immunizationwithleishmaniainfantumreleasedproteinsconferspartialprotectionagainstparasiteinfectionwithapredominantth1specificimmuneresponse
‡A
Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response.
‡9
1
|
|
919
|
|
|
‡a
potentialbenefitsofasulfatedresveratrolderivativefortopicalapplication
‡A
Potential benefits of a sulfated resveratrol derivative for topical application.
‡9
1
|
|
919
|
|
|
‡a
newinsightsintoneutrophilandleishmaniainfantuminvitroimmuneinteractions
‡A
New insights into neutrophil and Leishmania infantum in vitro immune interactions.
‡9
1
|
|
919
|
|
|
‡a
intraspecificvariabilityofvirulenceinleishmaniainfantumzymodememon1strains
‡A
Intra-specific variability of virulence in Leishmania infantum zymodeme MON-1 strains.
‡9
1
|
|
919
|
|
|
‡a
invitrocytotoxicityevaluationofresveratrolloadednanoparticlesfocusonthechallengesofinvitromethodologies
‡A
In vitro cytotoxicity evaluation of resveratrol-loaded nanoparticles: Focus on the challenges of in vitro methodologies
‡9
1
|
|
919
|
|
|
‡a
currentneurogenicandneuroprotectivestrategiestopreventandtreatneurodegenerativeandneuropsychiatricdisorders
‡A
Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.
‡9
1
|
|
919
|
|
|
‡a
immunizationwiththeleishmaniainfantumrecombinantcyclophilinprotein1conferspartialprotectiontosubsequentparasiteinfectionandgeneratesspecificmemorytcells
‡A
Immunization with the Leishmania infantum recombinant cyclophilin protein 1 confers partial protection to subsequent parasite infection and generates specific memory T cells.
‡9
1
|
|
919
|
|
|
‡a
analysisoftheprotectivepotentialofantigensreleasedbyleishmaniavianniashawipromastigotes
‡A
Analysis of the protective potential of antigens released by Leishmania (Viannia) shawi promastigotes.
‡9
1
|
|
919
|
|
|
‡a
analysisoftheprotectivepotentialofantigensreleasedbyleishmania
‡A
Analysis of the protective potential of antigens released by Leishmania
‡9
1
|
|
919
|
|
|
‡a
efficacyoftheliposometrifluralininthetreatmentofexperimentalcanineleishmaniosis
‡A
Efficacy of the liposome trifluralin in the treatment of experimental canine leishmaniosis.
‡9
1
|
|
919
|
|
|
‡a
tissueregulationofsomiticcolloidlike1geneexpression
‡A
Tissue regulation of somitic colloid-like1 gene expression
‡9
1
|
|
919
|
|
|
‡a
her2positivefelinemammarycarcinoma
‡A
HER2-positive feline mammary carcinoma
‡9
1
|
|
919
|
|
|
‡a
differentialexpressionofcytokinegenesamongsicklecelltrait
‡A
Differential expression of cytokine genes among sickle-cell-trait
‡9
1
|
|
919
|
|
|
‡a
sustaineddrugreleasebycontactlensesforglaucomatreatmentareview
‡A
Sustained drug release by contact lenses for glaucoma treatment-a review.
‡9
1
|
|
919
|
|
|
‡a
cxcr4anditsligandcxcl12displayoppositeexpressionprofilesinfelinemammarymetastaticdiseasewiththeexceptionofher2overexpressingtumors
‡A
CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors
‡9
1
|
|
919
|
|
|
‡a
differentialexpressionofcytokinegenesamongsicklecelltraithbasandnormalhbaachildreninfectedwithplasmodiumfalciparum
‡A
Differential expression of cytokine genes among sickle-cell-trait (HbAS) and normal (HbAA) children infected with Plasmodium falciparum.
‡9
1
|
|
919
|
|
|
‡a
detectionoftoxoplasmagondiioocystsinfreshvegetablesandberryfruits
‡A
Detection of Toxoplasma gondii oocysts in fresh vegetables and berry fruits
‡9
1
|
|
919
|
|
|
‡a
studiesinacoinfectionmurinemodelofplasmodiumchabaudichabaudiandleishmaniainfantuminterferongammaandinterleukin4mrnaexpression
‡A
Studies in a co-infection murine model of Plasmodium chabaudi chabaudi and Leishmania infantum: interferon-gamma and interleukin-4 mRNA expression.
‡9
1
|
|
919
|
|
|
‡a
serumsdf1levelsareareliablediagnosticmarkeroffelinemammarycarcinomadiscriminatingher2overexpressingtumorsfromothersubtypes
‡A
Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes
‡9
1
|
|
946
|
|
|
‡a
a
‡9
1
|
|
996
|
|
|
‡2
SUDOC|124686524
|
|
996
|
|
|
‡2
NTA|436965577
|
|
996
|
|
|
‡2
PTBNP|1639738
|
|
996
|
|
|
‡2
LC|no2007090970
|
|
996
|
|
|
‡2
BLBNB|000254168
|
|
996
|
|
|
‡2
PTBNP|1932453
|
|
996
|
|
|
‡2
PTBNP|1763968
|
|
996
|
|
|
‡2
PTBNP|1613987
|
|
996
|
|
|
‡2
PTBNP|1839182
|
|
996
|
|
|
‡2
CAOONL|ncf11699462
|
|
996
|
|
|
‡2
ISNI|0000000086986018
|
|
996
|
|
|
‡2
BLBNB|000431764
|
|
996
|
|
|
‡2
SZ|1029513058
|
|
996
|
|
|
‡2
PLWABN|9810657401005606
|
|
996
|
|
|
‡2
BIBSYS|11040805
|
|
996
|
|
|
‡2
DNB|1029513058
|
|
996
|
|
|
‡2
PTBNP|1928987
|
|
996
|
|
|
‡2
SUDOC|273509993
|
|
996
|
|
|
‡2
RERO|A000105494
|
|
996
|
|
|
‡2
PTBNP|1171887
|
|
996
|
|
|
‡2
PTBNP|1857573
|
|
996
|
|
|
‡2
LC|n 86853770
|
|
996
|
|
|
‡2
ISNI|0000000061601257
|
|
996
|
|
|
‡2
ISNI|0000000068177911
|
|
996
|
|
|
‡2
PTBNP|1548765
|
|
996
|
|
|
‡2
NTA|297542818
|
|
996
|
|
|
‡2
RERO|A018711268
|
|
996
|
|
|
‡2
BLBNB|000596583
|
|
996
|
|
|
‡2
NUKAT|n 2021084051
|
|
996
|
|
|
‡2
LC|n 93042154
|
|
996
|
|
|
‡2
BLBNB|001116599
|
|
996
|
|
|
‡2
PTBNP|1419100
|
|
996
|
|
|
‡2
ISNI|0000000079868590
|
|
996
|
|
|
‡2
DNB|133980006
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
